HCW Biologics Inc. has announced that it entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. on May 13, 2025. As part of the agreement, Armistice has been granted pre-funded warrants to purchase up to 513,140 shares of HCW Biologics' common stock at an exercise price of $0.0001 per share. On May 15, 2025, Armistice exercised some of these warrants, acquiring 177,140 shares, and further exercised additional warrants for 126,000 shares on May 21, 2025. As of May 22, 2025, Armistice retains the option to purchase an additional 210,000 shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.